HBM Holdings Limited

HBM Holdings Limited - ROEverified

HBMHF

Price:

$1.56

Market Cap:

$1.17B

HBM Holdings Limited is a biopharmaceutical company in the clinical development phase, dedicated to the discovery and advancement of differentiated antibody therapeutics for immunological and oncological disorders. The firm's robust pipeline includes several notable candidates: Batoclimab (HBM9161), a human monoclonal antibody designed to selectively bind to and inhibit the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036), intended to address moderate to severe dry eye disease; HBM7008, a bispecific antibody engineered to engage tumor-associated antigens; and HBM4003, a human anti-CTLA-4 antibody directed against cytotoxic T-lymphocyte-associated antigen-4. Furthermore, HBM ...[Read more]

Industry

Biotechnology

IPO Date

2022-03-24

Stock Exchange

OTC

Ticker

HBMHF

The ROE as of June 2026 (TTM) for HBM Holdings Limited (HBMHF) is 17.09%

According to HBM Holdings Limited’s latest financial reports and current stock price. The company's current ROE is 17.09%. This represents a change of 236.96% compared to the average of 5.07% of the last 4 quarters.

HBM Holdings Limited (HBMHF) Historical ROE (quarterly & annually)

How has HBMHF ROE performed in the past?

The mean historical ROE of HBM Holdings Limited over the last ten years is -20.17%. The current 17.09% ROE has changed -184.72% with respect to the historical average. Over the past ten years (40 quarters), HBMHF's ROE was at its highest in in the June 2020 quarter at 23.98%. The ROE was at its lowest in in the December 2022 quarter at -69.13%.

Quarterly (TTM)
Annual

Average

-20.17%

Median

10.62%

Minimum

-147.88%

Maximum

44.00%

HBM Holdings Limited (HBMHF) ROE by Quarter and Year

Discovering the peaks and valleys of HBM Holdings Limited ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 1.02%

Maximum Annual ROE = 44.00%

Minimum Annual Increase = -286.61%

Minimum Annual ROE = -147.88%

Quarterly (TTM)
Annual
YearROEChange
202524.91%1.02%
20242.23%-88.25%
202319.00%-112.85%
2022-147.88%139.38%
2021-61.78%-24.76%
2020-82.10%-286.61%
201944.00%9.25%

HBM Holdings Limited (HBMHF) Average ROE

How has HBMHF ROE performed in the past?

The current ROE of HBM Holdings Limited (HBMHF) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

15.38%

5-year avg

-32.70%

10-year avg

-20.17%

HBM Holdings Limited (HBMHF) ROE vs. Peers

How is HBMHF’s ROE compared to its peers?

HBM Holdings Limited’s ROE is greater than Anebulo Pharmaceuticals, Inc. (-74.58%), greater than Rezolute, Inc. (-58.82%), greater than HCW Biologics Inc. (-102.39%), greater than Eliem Therapeutics, Inc. (-31.46%), greater than Molecular Partners AG (-66.19%), less than TRACON Pharmaceuticals, Inc. (90.15%), less than XOMA Royalty Corp. (30.21%), greater than Sio Gene Therapies Inc. (-78.26%), greater than Vincerx Pharma, Inc. (-542.55%), greater than Virpax Pharmaceuticals, Inc. (-2364.82%), greater than Acurx Pharmaceuticals, Inc. (-153.93%), greater than MediciNova, Inc. (-27.29%), greater than NextCure, Inc. (-186.96%), greater than Entera Bio Ltd. (-87.97%), greater than Day One Biopharmaceuticals, Inc. (-23.43%), greater than Acumen Pharmaceuticals, Inc. (-123.07%), greater than X4 Pharmaceuticals, Inc. (-94.90%), greater than Inozyme Pharma, Inc. (-122.99%), greater than VectivBio Holding AG (-56.92%), less than Bio-Path Holdings, Inc. (76.46%), less than Endonovo Therapeutics, Inc. (6.45%), greater than Cingulate Inc. (-365.16%), greater than Purple Biotech Ltd. (-123.47%), less than Soleno Therapeutics, Inc. (22.86%),

Build a custom stock screener for HBM Holdings Limited (HBMHF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like HBM Holdings Limited using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

HBM Holdings Limited (HBMHF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like HBM Holdings Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the ROE?

How can you use the ROE?

What is HBM Holdings Limited's ROE?

How is the ROE calculated for HBM Holdings Limited (HBMHF)?

What is the highest ROE for HBM Holdings Limited (HBMHF)?

What is the 3-year average ROE for HBM Holdings Limited (HBMHF)?

What is the 5-year average ROE for HBM Holdings Limited (HBMHF)?

How does the current ROE for HBM Holdings Limited (HBMHF) compare to its historical average?